1Biomarkers Definitions Working Group. Arthur J. Atkinson J, Wayne AC, Victor GD, et al. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework [J]. Clin Pharmacol Ther, 2001,69(3) :89-95.
2Mary V,Relling,Tierry Dervieux. Pharmacogenetics and cancer therapy[J]. Nature Review Cancer,2001,1 (2):99-107.
3Vogelzang NJ, Rusthoven J J, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus eisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003,21 (14) : 2636-2644.
4Hanna N,Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol,2004,22(9) : 1589-97.
5Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oneol, 2008,26(21 ) : 3543.
6Stavit D,Gerrit J,Robert M,et al. Assaraf. Clustering of Mutations in the First Transmembrane Domain of the Human Reduced Folate Carrier in GW1843U89-resistant Leukemia Cells with Impaired Antifolate Transport and Augmented Folate Uptake[J]. JBC,2000,40(6) :30855-30863.
7Theti DS,Jackman AL. The role of α-folate receptor-mediated transport in the antitumor activity of antifolate drugs[J]. Clin Cancer Res, 2004,10 (3) : 1080-1089.
8Zhao R, Gao F, Hanscom M, et al. A Prominent Low-PH Methotrexate Transport Activity in Human Solid Tumor Cells:Contribution to the Preservation of Methotrexate Pharmacological Activity in HeLa Cells Lacking theReduced Folate Carrier[J]. Clin Cancer Res, 2004,10 (2) : 718-727.
9Agnieszka B, Patrycja W, Magorzata B. Cellular aspects of folate and antifolate membrane transport[J]. Acta Biochimica Polonica, 2000,47 (3) : 735-749.
10Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gammaglutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines[J]. Int J Cancer, 2003, 103 (5) :587-599.
5OHE Y. Chemoradiotherapy for lung cancer[ J] . Expert Opin Pharmacother, 2005, 6 (16) : 2793 - 2804.
6ADJEI AA. Pharmacology and mechanism of action of pemetrexed [J]. Clin Lung Cancer, 2004, 5(Suppl 2): S51 -S55.
7SHEPHERD FA, DANCEY J, RAMLAU R, et al. Prospectiw. randomized trial of docetaxel versus best supportive care in patients with non small-cell lung cancer previously treated with plat- inum-based chemotherapy[ J ]. J Clin Oncol, 2000, 18 ( 10): 2095 - 2103.
8JUNI P, ALTMAN DG, EGER M. Assessing the quality of controlled Clinical Trails [ J ]. BMJ, 2001 , 323 ( 7303 ) : 42 - 46.
9HANNA N, SHEPHERD FA, FOSSELLA FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J]. JClin Oncol, 2004, 22(9) :1589-1597.
10VERGNENEGRE A,CORRE R,BERARD H, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, malticenter phase 111 trial comparing docetaxel and pemetrexed: the GFPC 054)6 study [J]. J Thorac Oncol, 2011, 6(1) :161 -168.
